Skip to main content

Zimmer Biomet Holdings Value Stock - Dividend - Research Selection

Zimmer

ISIN: US98956P1021 , WKN: 753718

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Zimmer Biomet Holdings, Inc., together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental. The company provides orthopaedic reconstructive products, such as knee and hip replacement products; S.E.T. products, including surgical, sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products; and bone cement and spinal fusion stimulators. The company\'s products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopaedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Barclays Maintains Underweight on Zimmer Biomet Holdings, Lowers Price Target to $100

2026-02-12
Barclays analyst Matt Miksic maintains Zimmer Biomet Holdings (NYSE:ZBH) with a Underweight and lowers the price target from $104 to $100.

Enovis: Valuation Is Too Low, But Needs To Differentiate On Growth

2026-02-12
Enovis management has guided for up to low-double-digit Recon growth in 2026. Learn more about ENOV stock and why I maintain my buy rating.

Zimmer Biomet Holdings Inc (ZBH) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ...

2026-02-12
Zimmer Biomet Holdings Inc (ZBH) reports robust Q4 2025 performance with a 5.4% organic revenue growth and outlines plans for a dedicated US sales channel by 2027.

Zimmer Biomet (ZBH) Is Up 6.1% After Earnings Beat And New Buyback Plan Is Announced

2026-02-11
Zimmer Biomet Holdings, Inc. reported its fourth-quarter and full-year 2025 results, with Q4 sales rising to US$2,243.8 million from US$2,023.2 million a year earlier, while quarterly net income fell to US$139.3 million from US$239.4 million. Alongside the earnings release, Zimmer Biomet completed a prior US$1,229.78 million buyback and authorized a new US$1,500 million repurchase program, signaling continued emphasis on returning capital to shareholders despite lower earnings. We’ll now...

Zimmer plans US salesforce reorganization

2026-02-11
Zimmer Biomet expects the shift of its U.S. salesforce to a more specialized, direct approach will help it better compete in the orthopedics market.

Wells Fargo Maintains Equal-Weight on Zimmer Biomet Holdings, Raises Price Target to $98

2026-02-11
Wells Fargo analyst Larry Biegelsen maintains Zimmer Biomet Holdings (NYSE:ZBH) with a Equal-Weight and raises the price target from $93 to $98.

Zimmer Biomet Stock: Is Wall Street Bullish or Bearish?

2026-02-11
Zimmer Biomet has trailed the broader market over the past year, and it continues to face skeptical sentiment from analysts regarding its near- to medium-term growth outlook.

Zimmer Biomet Q4 Earnings Call Highlights

2026-02-11
Zimmer Biomet (NYSE:ZBH) reported fourth-quarter 2025 results that management said met its commitments on sales growth, earnings, and free cash flow despite tariff headwinds and the integration of three acquisitions during the year. Executives also outlined a major ongoing shift in the company’s U.S

ZBH Q4 Deep Dive: U.S. Salesforce Overhaul Drives Guidance Caution Amid Product Momentum

2026-02-11
Medical device company Zimmer Biomet (NYSE:ZBH) reported Q4 CY2025 results topping the market’s revenue expectations, with sales up 10.9% year on year to $2.24 billion. Its non-GAAP profit of $2.42 per share was 0.9% above analysts’ consensus estimates.

Zimmer Biomet reports 2025 revenue growth yet tempers 2026 outlook

2026-02-10
Zimmer’s CEO said its 2026 outlook remains cautious as it focuses on product adoption, a US salesforce transition, and international market performance.